SCHEMBL3276205

SCHEMBL3276205

Clc1ccc2cccc(CBr)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.43
CYP1A2 P05177 4/20 0.40
CYP2C19 P33261 3/20 0.40
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP2C9 P11712 2/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 1/20 0.37
ALPG P10696 1/20 0.37
HTT P42858 1/20 0.37
NR4A2 P43354 1/20 0.36
CHEK1 O14757 1/20 0.35
FADS1 O60427 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
CYP19A1 P11511 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
GPR84 Q9NQS5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27366935 0.85 CYP2A6 (0.41) CYP2A6CYP1A2CYP2C19MEN1KMT2A
SCHEMBL11584656 0.82 CYP2A6 (0.45) CYP2A6CYP1A2CYP2C19MEN1KMT2A
SCHEMBL29792747 0.82 CYP2A6 (0.45) CYP2A6CYP1A2CYP2C19MEN1KMT2A
SCHEMBL16629592 0.81 CYP2A6 (0.43) CYP2A6CYP1A2CYP2C19MEN1KMT2A
SCHEMBL18015817 0.81 CYP2A6 (0.43) CYP2A6CYP1A2CYP2C19MEN1KMT2A
SCHEMBL3571906 0.81 CYP2A6 (0.43) CYP2A6CYP1A2CYP2C19MEN1KMT2A
SCHEMBL29792638 0.81 CYP2A6 (0.43) CYP2A6CYP1A2CYP2C19MEN1KMT2A
SCHEMBL15352213 0.81 CYP2A6 (0.43) CYP2A6CYP1A2CYP2C19MEN1KMT2A
SCHEMBL3570495 0.81 CYP2A6 (0.47) CYP2A6CYP1A2CYP2C19MEN1KMT2A
Hydrochloric Acid SCHEMBL3580262 0.79 CYP2A6 (0.46) CYP2A6CYP1A2CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1966134-B1 NOVEL FUSED PYRROLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-7696240-B2 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-04-13 US disclosed
EP-1966134-A1 NOVEL FUSED PYRROLE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-09-10 EP disclosed
WO-2007068621-A1 NOVEL FUSED PYRROLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-06-21 WO disclosed
US-20070142452-A1 Fused pyrrole derivatives HOFFMANN-LA ROCHE INC. 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142452-A1 Fused pyrrole derivatives CMA1, PREP, CPA3 CYP2A6 878/4885CYP1A2 580/4885CYP2C19 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.